🟢 Eupraxia Pharmaceuticals is trading 12.1% up in pre-market amid higher U.S. indices

Eupraxia Pharmaceuticals is trading at $7.42, +12.08% before the October 19 session, with broader risk-on sentiment possibly contributing.

• U.S. indices are higher; the Nasdaq Composite is up 1.17%.
• An oral abstract is scheduled for UEG Week on October 19; the announcement dates to October 9 and provides no new results.
• The 120-patient RESOLVE Phase 2b enrollment target was announced October 15; interim data are expected in December.